# IPCA Laboratories (NSE: IPCALAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/IPCALAB · Pivot · prices to 22 Oct 2026

IPCA Laboratories (NSE: IPCALAB) closed at ₹1,932.90 on 22 Oct 2026, up 0.62% on the day. With a market capitalisation of ₹48,293 Cr, it ranks 195th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 43× trailing earnings, against a return on equity of 14.2% in FY26. Over the past year the share price has risen 48.4%. Its 52-week range is ₹1,251.60 (24 Oct 2025) to ₹2,038.00 (18 Sep 2026); the last close is 5.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,388 Cr (+6.3% year on year) and net profit ₹309 Cr (+370.4%), on a consolidated basis. Promoters held 44.72% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,932.90 |
| Market cap | ₹48,293 Cr |
| P/E (trailing) | 43 |
| ROE | 14.2% (FY26) |
| ROCE | 17.2% (FY26) |
| Debt to equity | 0.09 |
| 52-week high | ₹2,038.00 (18 Sep 2026) |
| 52-week low | ₹1,251.60 (24 Oct 2025) |
| 1-year return | +48.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹2,388 Cr | +6.3% | ₹309 Cr | +370.4% | ₹13.31 |
| Q3 FY26 | ₹2,393 Cr | +6.6% | ₹364 Cr | +31.3% | ₹12.09 |
| Q2 FY26 | ₹2,557 Cr | +8.6% | ₹284 Cr | +15.5% | ₹12.35 |
| Q1 FY26 | ₹2,309 Cr | +10.3% | ₹234 Cr | +17.8% | ₹9.19 |
| Q4 FY25 | ₹2,247 Cr | +10.5% | ₹66 Cr | +2,160.5% | ₹2.67 |
| Q3 FY25 | ₹2,245 Cr | +9.4% | ₹277 Cr | +24.6% | ₹9.78 |
| Q2 FY25 | ₹2,355 Cr | +15.8% | ₹245 Cr | +78.6% | ₹9.05 |
| Q1 FY25 | ₹2,093 Cr | +31.8% | ₹199 Cr | +19.7% | ₹7.58 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹8,940 Cr | ₹788 Cr |
| FY24 | ₹7,705 Cr | ₹529 Cr |
| FY23 | ₹6,244 Cr | ₹492 Cr |
| FY22 | ₹5,830 Cr | ₹911 Cr |
| FY21 | ₹5,420 Cr | ₹1,149 Cr |
| FY20 | ₹4,649 Cr | ₹611 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 44.72%
- Foreign institutions: 10.73%
- Domestic institutions: 37.37%
- Non-institutions: 7.18%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹647.20 | ₹57,068 Cr | 101.1 | 8.5% |
| [Fortis Healthcare](https://app.pivotnow.in/stock/FORTIS) | ₹720.15 | ₹54,859 Cr | 52.3 | 10.5% |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹53,888 Cr | 34.8 | 33.4% |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹53,829 Cr | 117.6 | 1.1% |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | ₹2,910.60 | ₹47,020 Cr | 46.7 | 9.9% |
| [Anthem Biosciences](https://app.pivotnow.in/stock/ANTHEM) | ₹802.40 | ₹45,113 Cr | 76.6 | 19.4% |

## Questions and answers

### What is the share price of IPCA Laboratories today?

IPCA Laboratories (NSE: IPCALAB) last closed at ₹1,932.90 on 22 Oct 2026. Its 52-week high is ₹2,038.00 and its 52-week low is ₹1,251.60.

### What is the market cap of IPCA Laboratories?

IPCA Laboratories' market capitalisation is ₹48,293 Cr (₹48,293 Cr) at the 22 Oct 2026 close, ranking 195th among the NSE companies Pivot tracks.

### What is the P/E ratio of IPCA Laboratories?

IPCA Laboratories trades at a trailing P/E of 43. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 76.6.

### What is the ROE and ROCE of IPCA Laboratories?

Return on equity was 14.2% in FY26 and return on capital employed was 17.2% in FY26 (consolidated figures).

### Is IPCA Laboratories a debt-free company?

No. IPCA Laboratories' debt-to-equity ratio was 0.09 in FY26, with total debt of ₹109 Cr.

### What were IPCA Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), IPCA Laboratories reported revenue of ₹2,388 Cr, +6.3% year on year, and net profit of ₹309 Cr, +370.4% year on year.

### How has IPCA Laboratories stock performed over the last year?

IPCA Laboratories' share price has risen 48.4% over the past year, +7.9% over three months and −3.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of IPCA Laboratories?

As of 30 Jun 2026: promoters 44.72%, foreign institutions 10.73%, domestic institutions 37.37%, non-institutions 7.18%.

### Who are IPCA Laboratories' competitors?

The listed Pharma & Healthcare companies closest to IPCA Laboratories by market cap are Aster DM Health, Fortis Healthcare, Abbott India, Biocon, Gland Pharma and Anthem Biosciences.

### Is IPCA Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out IPCA Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on IPCALAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.